Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
If you're considering switching between injection and oral, your PlexusDx provider will recalculate your therapeutic dose accordingly
Based on current phase 3 TRIUMPH trial timelines, a regulatory submission to the MHRA is not anticipated before 20262027 at the earliest, with a possible marketing authorisation in 20272028 and NHS availability potentially from 2028 onwards, subject to NICE appraisal
Please contact your local PPS for possible participation
N Engl J Med 392(5):427437 Pratley RE, Tuttle KR, Rossing P, Rasmussen S, Perkovic V, Nielsen OW et al (2024) Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial
Consistent with this, we show the G protein can allosterically influence GLP-1R agonist affinity, but this occurs in a peptide-dependent manner
Some doctors might consider combining treatments (though currently, combining GLP-1 with another weight loss drug is not very common, its an area of research)
